Sequoia Sciences Backed by Prolog Ventures, Holton Capital
December 31, 2012
Prolog Ventures and Holton Capital have anted up $1.5 million in later-stage venture funds for Sequoia Sciences, a drug developer based in St. Louis, MO. According to the company’s website, it is working to “provide new and alternative treatments for acute bacterial infections and chronic infections involving bacterial biofilms,” including a vaccine that may treat chronic female urinary-tract infections. The recent influx of capital will go toward the clinical development of this vaccine.